产品
编 号：F281989
分子式：C30H30F2N6O3
分子量：560.59
分子式：C30H30F2N6O3
分子量：560.59
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2252403-56-6
产品详情
生物活性：
Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research.
体内研究：
Sotorasib racemate (30-100 mg/kg, 口服, 每日一次, 21 d) 剂量依赖性地抑制肿瘤异种移植小鼠中的 NCI-H358 肿瘤生长。Animal Model:Female NOD/SCID mice, tumor xenograft model of NCI-H358 cells which harbor KRAS G12C (human NSCLC cell)
Dosage:10, 30, 100 mg/kg
Administration:Oral gavage (p.o.), QD for 21 d
Result:Suppressed the growth of the NCI-H358 tumors in a dose-dependent manner, observed significant tumor regression at 100 mg/kg and 30 mg/kg with tumor growth inhibition of 137% and 126%, respectively.
Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research.
体内研究：
Sotorasib racemate (30-100 mg/kg, 口服, 每日一次, 21 d) 剂量依赖性地抑制肿瘤异种移植小鼠中的 NCI-H358 肿瘤生长。Animal Model:Female NOD/SCID mice, tumor xenograft model of NCI-H358 cells which harbor KRAS G12C (human NSCLC cell)
Dosage:10, 30, 100 mg/kg
Administration:Oral gavage (p.o.), QD for 21 d
Result:Suppressed the growth of the NCI-H358 tumors in a dose-dependent manner, observed significant tumor regression at 100 mg/kg and 30 mg/kg with tumor growth inhibition of 137% and 126%, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备